Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cosciens Biopharma's share price for the quarter that ended in Mar. 2026 was $1.024. Cosciens Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 3.18 Mil. Therefore, Cosciens Biopharma's market cap for the quarter that ended in Mar. 2026 was $3.26 Mil.
Cosciens Biopharma's quarterly market cap
declined
from Sep. 2025 ($7.86 Mil) to Dec. 2025 ($6.56 Mil) and
declined
from Dec. 2025 ($6.56 Mil) to Mar. 2026 ($3.26 Mil).
Cosciens Biopharma's annual market cap
declined
from Dec. 2023 ($12.94 Mil) to Dec. 2024 ($8.70 Mil) and
declined
from Dec. 2024 ($8.70 Mil) to Dec. 2025 ($6.56 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cosciens Biopharma's Enterprise Value for Today is $1.19 Mil.
Cosciens Biopharma (OTCPK:CSCIF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cosciens Biopharma Market Cap Related Terms
Cosciens Biopharma Market Cap Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cosciens Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cosciens Biopharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCIF) has a Market Cap of $6.30 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cosciens Biopharma and its competitors. According to the industry distribution chart, Cosciens Biopharma ranks #1259 out of 1430 companies in the Biotechnology industry, placing it in the top 88%.
Is Cosciens Biopharma's Market Cap too high?
Cosciens Biopharma's current Market Cap is $6.30 Mil. The Biotechnology industry median Market Cap is 117.26. Cosciens Biopharma's value of $6.30 Mil is 94.6% below this industry median. Based on the distribution chart, Cosciens Biopharma ranks #1259 out of 1430 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cosciens Biopharma has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #1259 out of 1430 companies for Market Cap. This places Cosciens Biopharma in the lower half of its industry. The industry median Market Cap is 117.26. Cosciens Biopharma's value of $6.30 Mil is 94.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Market Cap of $6.30 Mil is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cosciens Biopharma and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Market Cap is $6.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.35, compared to a current price of $1.99 — trading 15.3% below its estimated fair value. The current Market Cap is $6.30 Mil and 94.6% below the Biotechnology industry median of 117.26. Cosciens Biopharma's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Market Cap is $6.30 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $1.99 is trading 15.3% below its estimated GF Value™ of $2.35.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
Market Cap: $6.30 Mil
GF Value™: $2.35 vs. price of $1.99 (15.3% below fair value)
Industry Position: 94.6% below the Biotechnology median (#1259 of 1430)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
62GF Score
Get the complete analysis for CSCIF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
